期刊文献+

创新霉素生物合成研究进展

Research progress on the biosynthesis of chuangxinmycin
下载PDF
导出
摘要 创新霉素是中国科学家20世纪60年代发现的具有全新骨架结构的抗生素,由济南游动放线菌产生,具有良好的抗菌活性和新颖的作用靶点,但创新霉素的生物合成基因簇在其发现50多年后才得到解析。本文介绍了创新霉素研究的历史沿革,着重介绍了其生物合成机制的最新研究进展,从生物合成基因簇、生物合成途径、新颖的去泛素化酶样的硫转移酶催化的硫掺入机制、罕见的细胞色素P450酶催化的C-S键形成机制等角度进行阐述,这些研究进展为利用组合生物合成和合成生物学技术进行新药研发和高产优产奠定了理论基础。 Chuangxinmycin is an antibiotic isolated from Actinoplanes tsinanensis in the 1960s with a novel indole-dihydrothiopyran heterocyclic skeleton.It showed good antibacterial activity and unique antibacterial mechanism.However,its biosynthetic gene cluster has remained obscure for over 50 years.The historical evolution of chuangxinmycin research was introduced,and the latest advances in the understanding of its biosynthetic mechanism were reviewed in detail from the perspectives of biosynthetic gene cluster,biosynthetic pathway,the novel mechanism for sulfur incorporation catalyzed by a deubiquitinase-like sulfurtransferase and the rare C-S bond formation mechanism catalyzed by cytochrome P450 enzyme.The elucidation of the biosynthetic mechanism of chuangxinmycin provides the basis for applying combinatorial biosynthesis and synthetic biology technology in generating diverse structures for new drug discovery and development.
作者 侍媛媛 武临专 洪斌 Shi Yuan-yuan;Wu Lin-zhuan;Hong Bin(NHC Key Laboratory of Biotechnology of Antibiotics,CAMS Key Laboratory of Synthetic Biology for Drug Innovation,Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050)
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2023年第3期343-350,共8页 Chinese Journal of Antibiotics
基金 国家重点研发计划(No.2018YFA0902000) 国家自然科学基金(No.81872780和No.81803410) 中国医学科学院医学与健康科技创新工程(No.2018-I2M-3-005) 北京市自然科学基金(No.7184227)
关键词 创新霉素 生物合成 C-S键形成 硫掺入 细胞色素P450酶 Chuangxinmycin Biosynthesis C-S bond formation Sulfur incorporation Cytochrome P450 enzyme
  • 相关文献

参考文献6

二级参考文献14

  • 1曹兢,戚天庆.创新霉素产生菌吲哚丙酮酸甲基转移酶的研究[J].微生物学报,1989,29(1):63-67. 被引量:2
  • 2王立军,抗生素,1986年,11卷,4期,338页
  • 3林卓坤,色谱法.1,1982年
  • 4戚天庆,中国医学科学院学报,1980年,2卷,32页
  • 5Cheng G, Dai M, Ahmed S, et al. Antimicrobial drugs in fighting against antimicrobial resistance. Front Microbiol, 2016, 7:470.
  • 6Rossolini GM, Arena F, Pecile P, et al. Update on the antibiotic resistance crisis. Curr Opin Pharmacol, 2014, 18:56-60.
  • 7Lee HH, Molla MN, Cantor CR, et al. Bacterial charity work leads to population-wide resistance. Nature, 2010, 467(7311):82-85.
  • 8Willems RJ, Hanage WP, Bessen DE, et al. Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol Rev, 2011, 35(5):872-900.
  • 9Singh SB, Rindgen D, Bradley P, et al. Design, synthesis, structure-function relationship, bioconversion, and pharrnacokinetic evaluation of ertapenem prodrugs. J Med Chem, 2014, 57(20):8421- 8444.
  • 10Gupta D, Varghese Gupta S, Dahan A, et al. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm, 2013, 10(2):512-522.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部